 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Under New Management, RXi Takes Aim at the Clinic, Wall Street
May 17, 2012
Under New Management, RXi Takes Aim at the Clinic, Wall Street
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- People in the News: Paul Dorman, Curtis Lockshin
April 25, 2013 / Gene Silencing News - Following Private Placement, RXi Has Funds to Last into 2015
April 4, 2013 / Gene Silencing News - RXi Releases Blinded Phase I Data Hinting at Efficacy of Anti-Scarring Drug, On Track for Phase II
February 21, 2013 / Gene Silencing News - RXi Begins Second Phase I Trial of Anti-Scarring Drug
December 6, 2012 / Gene Silencing News - RXi Releases Positive Safety Data on Scarring Drug, Posts Higher Q3 Loss on Dividend
November 15, 2012 / Gene Silencing News